{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-028518","form_type":"8-K","ticker":"BIAF","cik":"0001712762","company_name":"bioAffinity Technologies, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.955777+00:00","generated_at":"2026-06-11T11:46:43.045938+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"bioAffinity Tech Q2 net loss widens to $1.7M; revenue $20k; cash $8.3M","bullets":["Net loss of $1.7M ($0.20/sh) vs $88k ($0.03/sh) in Q2 2022; SG&A up to $1.4M from $409k.","Revenue of $20k, up from $1k YoY, including $10k from DOD sales of CyPath Lung.","Cash and equivalents $8.3M at June 30, 2023, down from $11.4M at Dec 31, 2022.","AMA issued CPT code for CyPath Lung effective Oct 1, 2023; DOD purchased tests.","Michael Dougherty appointed CFO; previously CFO of Amazon's Alexa commercial domains."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-028518","json":"https://secwatch.observer/filing/0001493152-23-028518.json","markdown":"https://secwatch.observer/filing/0001493152-23-028518.md","text":"https://secwatch.observer/filing/0001493152-23-028518.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1712762/000149315223028518/0001493152-23-028518-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1712762/000149315223028518/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T11:46:43.045938+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2509c50d55c177c99a72f7fdde81a051f10f5527","claim":"bioAffinity Technologies, Inc. reported second quarter of 2023; three and six months ended June 30, 2023 results: revenue $20,000, net income $1.7 million, EPS $0.20 per share.","evidence_excerpt":"Revenue for the second quarter of 2023 was $20,000, compared with $1,000 for the prior-year period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1712762/000149315223028518/0001493152-23-028518-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter of 2023; three and six months ended June 30, 2023"},{"label":"Revenue","value":"$20,000"},{"label":"Net income","value":"$1.7 million"},{"label":"EPS","value":"$0.20 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}